Immuron Ltd (IMRN) SEC Filings, Feb-Apr 2026

Immuron Ltd’s Chief Executive Officer Steven George Lydeamore has filed an initial ownership report. He directly holds 3,155,047 Ordinary Shares. He also holds 1,778,734 Performance Rights that vest upon achievement of performance milestones and options over 1,430,000 Ordinary Shares with a USD exercise price of $0.0861 per share, expiring on June 27, 2026.

Immuron Ltd director Ravi Savarirayan has filed an initial Form 3 detailing his ownership in the company. He reports direct ownership of 409,090 Ordinary Shares and indirect ownership of 468,750 Ordinary Shares through joint ownership with Sophie Beaumont.

He also holds options over 1,000,000 Ordinary Shares at an exercise price of $0.0789 per share, expiring on October 3, 2029, and options over 333,333 Ordinary Shares at an exercise price of $0.1040 per share, expiring on August 20, 2028. Footnotes describe staged vesting of these options across 2025–2028 and indicate the exercise prices were originally denominated in Australian dollars and translated into U.S. dollars using a Reserve Bank of Australia exchange rate.

Immuron Limited reports continued unaudited sales growth for its over-the-counter gastrointestinal supplement Travelan® in Q3 FY26. In Australia, Travelan® sales rose 15% on the prior corresponding period, helped by digital and social media marketing, stronger in-store promotion, new banner-group store listings, and increased South East Asian travel.

In the U.S., Q3 Travelan® sales increased 1% on the prior corresponding period, supported by an improved Amazon.com store, local social media pages, and expanded paid and influencer marketing, partly offset by a stronger Australian dollar against the U.S. dollar. In Canada, after a Q1 pipeline fill into over a thousand retail doors and a 191% Q2 FY26 sales increase over the prior quarter, Q3 FY26 Travelan® sales grew a further 82% on the prior quarter as brand awareness and in-store programs expanded.

Immuron Limited has set up a Small Holding Share Sale Facility for shareholders whose Immuron holdings were worth less than $500 as of the 8 April 2026 Record Date. Based on a closing share price of $0.027, this covers holdings of 18,518 shares or fewer.

Nearly 1,500 of the company’s approximately 2,400 shareholders hold such Small Holdings. These investors can have their shares aggregated and sold without paying brokerage or handling costs, with Immuron covering those expenses. Holders who wish to keep their shares must return a Share Retention Form or increase their holding above $500 in value by 1 June 2026, otherwise their shares will be sold and proceeds remitted to them in Australian dollars.

Immuron Limited reports HY26 global sales revenue of A$4.2 million, up 5% on the prior year, driven by strong Travelan and ProIBS demand. Australian sales rose to A$3.3 million, up 13%, while North American revenue was A$0.9 million, down 18%, though U.S. sales within that increased 17%.

Cash was A$10.0 million at 31 December 2025, up A$7.2 million from 30 June 2025, with EBITDX (ex-R&D) of -A$1.1 million. The company is resetting its strategy by seeking partners for its clinical assets IMM-124E for traveler’s diarrhea and IMM-529 for recurrent C. difficile infection, aiming to have licensees fund further development and commercialization while Immuron focuses on over-the-counter products Travelan and ProIBS.

Immuron Limited reported half-year 2026 revenue of A$4.18 million, up about 5% from the prior year, driven mainly by its Travelan hyperimmune products. Australia led with A$3.19 million in Travelan sales and 11% growth, while U.S. Travelan sales rose 17% to A$0.85 million; Canada declined.

The group’s net loss narrowed to A$1.92 million from A$2.49 million, with gross profit of A$2.65 million and a 63% margin. Hyperimmune products generated operating profit of A$0.98 million, helping lift net assets to A$13.08 million and cash to A$9.99 million after equity raises.

Strategically, Immuron gained FDA approval of an Investigational New Drug application for IMM-529 targeting Clostridioides difficile infection and is positioning the candidate for a Phase 2 trial aimed at recurrent cases. The company also launched PROIBS for irritable bowel syndrome in Australia and continues military-linked collaborations on new oral therapeutics for Campylobacter and Shigella.

Immuron Limited reported receiving an R&D Tax Incentive refund of A$1,121,885 from the Australian Government for eligible research and development activities conducted in the financial year ending June 30, 2025. This government program refunds 43.5% of eligible R&D expenditure.

The company describes this as non‑dilutive funding, helping it invest in growing sales and profitability while preserving financial flexibility. Immuron is planning profitability growth of its Hyper-Immune products and, together with cost reduction initiatives, is targeting improved EBITDX (ex‑R&D) in FY26.

Immuron Limited filed a Form 6-K to furnish results of its 2026 Extraordinary General Meeting. Shareholders passed all resolutions in the Notice of Meeting by poll.

Two ordinary resolutions ratifying prior issues of shares under ASX Listing Rules 7.1 and 7.1A were carried, with poll votes of 63.95% for and 36.05% against on each resolution.

Immuron Limited reported leadership changes effective 9 February 2026, with Mr Phillip Hains resigning as Chief Financial Officer and Company Secretary after serving since 2013. The company appointed Olga Smejkalova as Company Secretary and Aaron Laurita as Chief Financial Officer on the same date.

The announcement notes Ms Smejkalova will handle ASX Listing Rule communications and highlights both appointees’ governance, finance and commercial experience. The filing also reiterates Immuron’s focus on orally delivered targeted polyclonal antibodies and provides background on its Travelan product for travelers’ diarrhea.